Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Depreciation & Amortization (CF): 2009-2025

Historic Depreciation & Amortization (CF) for Lifecore Biomedical (LFCR) over the last 16 years, with May 2025 value amounting to $1.9 million.

  • Lifecore Biomedical's Depreciation & Amortization (CF) fell 4.97% to $1.9 million in Q2 2025 from the same period last year, while for May 2025 it was $8.0 million, marking a year-over-year increase of 0.92%. This contributed to the annual value of $8.0 million for FY2025, which is 0.92% up from last year.
  • Per Lifecore Biomedical's latest filing, its Depreciation & Amortization (CF) stood at $1.9 million for Q2 2025, which was down 7.80% from $2.1 million recorded in Q1 2025.
  • In the past 5 years, Lifecore Biomedical's Depreciation & Amortization (CF) registered a high of $5.9 million during Q4 2021, and its lowest value of $1.8 million during Q4 2023.
  • In the last 3 years, Lifecore Biomedical's Depreciation & Amortization (CF) had a median value of $2.0 million in 2024 and averaged $2.2 million.
  • As far as peak fluctuations go, Lifecore Biomedical's Depreciation & Amortization (CF) rose by 25.51% in 2021, and later plummeted by 50.41% in 2022.
  • Quarterly analysis of 5 years shows Lifecore Biomedical's Depreciation & Amortization (CF) stood at $5.9 million in 2021, then plummeted by 50.41% to $2.9 million in 2022, then tumbled by 39.93% to $1.8 million in 2023, then climbed by 15.74% to $2.0 million in 2024, then fell by 4.97% to $1.9 million in 2025.
  • Its Depreciation & Amortization (CF) was $1.9 million in Q2 2025, compared to $2.1 million in Q1 2025 and $2.0 million in Q4 2024.